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Our laboratory has previously developed a qRT-PCR assay to assess drug efficacy on
the growth of Cryptosporidium parvum in vitro by detecting the levels of parasite 18S
rRNA. This approach displayed up to four orders of magnitude of linear dynamic range
and was much less labor-intensive than the traditional microscopic methods. However,
conventional qRT-PCR protocol is not very amendable to high-throughput analysis when
total RNA needs to be purified by lengthy, multi-step procedures. Recently, several
commercial reagents are available for preparing cell lysates that could be directly used
in downstream qRT-PCR analysis (e.g., Ambion Cell-to-cDNA kit and Bio-Rad iScript
sample preparation reagent). Using these reagents, we are able to adapt the qRT-PCR
assay into high-throughput screening of drugs in vitro (i.e., 96-well and 384-well formats
for the cultivation of parasites and qRT-PCR detection, respectively). This qRT-PCR
protocol is able to give a >150-fold linear dynamic range using samples isolated from
cells infected with various numbers of parasites. The new assay is also validated by the
NIH-recommended intra-plate, inter-plate, and inter-day uniformity tests. The robustness
and effectiveness of the assay are also confirmed by evaluating the anti-cryptosporidial
efficacy of paromomycin and by a small scale screening of compounds.
Keywords: Cryptosporidium parvum, in vitro, qRT-PCR, high-throughput screening, assay development,
paromomycin
Introduction
Cryptosporidium is a genus of protozoan pathogens belonging to the Phylum Apicomplexa that
infect humans and/or animals. Among them, C. parvum and C. hominis are the two major
species causing water-borne and food-borne diarrheal illness in humans (Baldursson and Karanis,
2011; Budu-Amoako et al., 2011). These two and some other species, including C. meleagridis,
C. muris, C. canis, and C. felis, also cause opportunistic infections in AIDS patients (AIDS-OIs)
that can be chronic and fatal (Thompson et al., 2005; Feasey et al., 2011; O’connor et al., 2011;
Shirley et al., 2012). A more recent multi-country study also revealed that Cryptosporidium is
one of the top five diarrheal-causing pathogens in children in developing countries, in which
the infection increased death rate and negatively affected the growth of children (Kotloff et al.,
2013). However, options to treat cryptosporidiosis are limited. In fact, only a single drug,
nitazoxanide (NTZ) is approved by the U.S. Food and Drug Administration (FDA) to treat
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human cryptosporidial infection in immunocompetent patients.
Moreover, NTZ is ineffective in treating cryptosporidiosis in
AIDS patients, and its efficacy in immunocompetent patients
is also debatable (Cabada and White, 2010; Feasey et al., 2011;
O’connor et al., 2011; Checkley et al., 2015).
Two approaches are commonly employed in early stages of
drug discovery against infectious diseases. Hits and leads may
be identified from new chemical entities by directly testing
their efficacies against an in vitro or in vivo model of disease
(traditional methods), or by screening compounds against drug
targets from a pathogen such as essential enzymes or receptors
(target-based methods). In the later case, identified hits/leads
will still be evaluated on their in vitro efficacy before being
advanced to in vivo drug testing. Therefore, the availability
of a good in vitro disease model is critical in drug discovery
against diseases including cryptosporidiosis. In vitro models of
cryptosporidial infection are available, including the cultivation
of C. parvum in HCT-8 or Caco-2 cells (Arrowood, 2002; Cai
et al., 2005; Karanis and Aldeyarbi, 2011). However, there is a
need for developing new methods that can efficiently evaluate
the parasite growth in response to drug treatment in high-
throughput or high-volume format. Conventional microscopic
examination to count the numbers of parasites stained chemically
or by immunofluorescence labeled antibodies is highly labor-
intensive and sometimes subjective, making it unsuitable for
testing a large number of drugs. ELISA and chemiluminescence
immunoassay methods were reported, but they appeared to
have relatively narrow linear dynamic ranges of detection (i.e.,
the ratio between the largest and smallest signal values of
detection is proportional to the difference between the two
samples, such as the relationship between the OD values
and concentrations of an antigen in an ELISA assay) and
heavily relying on the quality and availability of specific
antibodies.
More recent approaches include quantitating parasite loads by
quantitative PCR (qPCR), qRT-PCR and automated fluorescence
imaging analysis that are generally more advantageous than the
earlier methods. Among them, the qRT-PCR method originally
developed in our laboratory evaluates drug efficacy by detecting
the relative levels of parasite 18S rRNA transcripts, which displays
up to four orders of magnitude of linear dynamic range between
the cycle threshold (CT) value and the logarithm of the number
of oocyst inoculum (Cai et al., 2005; Ctrnáctá et al., 2010;
Zhang et al., 2012). However, classic qRT-PCR protocol is not
very amendable to the high-throughput or high-volume analysis
when total RNA needs to be purified by lengthy, multi-step
procedures.
Here we report an improved and simplified qRT-PCR protocol
for evaluating of drug efficacies against the growth of C. parvum
in vitro. This new protocol takes advantage of the commercially
available lysis buffers to prepare cell lysates that could be directly
used in downstream qRT-PCR analysis. We also re-optimized the
primers and procedures, and adapted the in vitro cultivation of
parasite in 96-well plates and real-time RT-PCR detection in 384-
well plates, making the protocol suitable for high-throughput or
high-volume evaluation of drug efficacy against the growth of C.
parvum in vitro.
Materials and Methods
Cultivation of Parasite In Vitro
Fresh oocysts of C. parvum (Iowa strain) were purchased from
Bunch Grass Farm (Deary, ID). Oocysts were further purified
by a Percoll-based gradient centrifugation method and surface
sterilized with 10% bleach for 7min on ice, followed by washes
with phosphate-buffered saline (PBS). Only C. parvum oocysts
less than 3 months old were used in all experiments. An ileocecal
colorectal adenocarcinoma cell line (HCT-8, ATCC # CCL-
244) was used to host the growth of C. parvum in vitro. One
day before the inoculation, HCT-8 cells were seeded in 96-well
plates (2.5 × 104 cells/well) containing RPMI 1640 medium
supplied with 10% fetal bovine serum (200µL medium/well in
all experiments) and allowed to grow overnight at 37◦C under
5% CO2 atmosphere until they reached ∼90% confluence. The
infection and growth of C. parvum in vitro in 96-well plates were
examined by differential interference contrast (DIC) microscopy
and immunofluorescence (IF) labeling using a rabbit polyclonal
antiserum raised against C. parvum sporozoite total membrane
proteins (Zeng and Zhu, 2006; Zeng et al., 2006; Fritzler et al.,
2007), and by qRT-PCR (as described below).
For generating standard curves, host cells were inoculated
with five-fold serial dilutions of parasite oocysts (i.e., 4 × 104–
64 oocysts/well), responding to the ratios between parasite and
host cells ranging from ∼1:1 to 1:625. For drug testing, host
cells were infected with 2 × 104 oocysts per well (i.e., ratio
1:2). After inoculation, parasite oocysts were allowed to undergo
excystation and invasion into host cells for 3 h at 37◦C. Free
parasites and oocyst walls in the medium were removed from the
plates by an exchange of the culture medium. Drugs at specified
concentrations were added into the culture at this time point
(i.e., immediately after the medium exchange). Parasite-infected
cells were then incubated at 37◦C for additional 41 h (i.e., total
44 h infection time). For dose response of paromomycin (PRM),
3× serial diluted PRM from 30 to 800µg/mL (i.e., 42–1120µM)
was added to infected cells after 3 h post-infection (hpi) and the
treatment lasted for 41 h. At least two independent experiments
were conducted for every experimental condition, each including
two replicates drugs and three replicates for negative and positive
controls.
Preparation of Cell Lysates
Plates containing HCT-8 cells infected with C. parvum for
44 h and uninfected cells grown under the same condition
were first centrifuged in a Sigma 2–5 plate centrifuge (Sigma
Laborzentrifugen GmbH, Germany) for 10min at 1000 × g to
ensure that free merozoites in the medium were firmly settled on
the bottom of the wells. Medium was removed by gentle flicking
the plate over a container placed in the biosafety cabinet, followed
by two gentle washes with PBS. After removal of PBS and blotting
plates on paper towels to remove remaining drops, plates were
placed on ice in a rectangle bucket. An eight-channel electronic
pipette (Rainin Instrument, Oakland, CA) was used to add PBS
and lysis buffer in subsequent procedures.
For extracting total RNA used in high-throughput screening
(HTS), 200µL of ice-cold Bio-Rad iScript qRT-PCR sample
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preparation reagent (lysis buffer) (Bio-Rad Laboratories,
Hercules, CA) was added into each well. Plates were sealed with
adhesive and heat sealing films and the bucket containing racked
plates on ice was secured in a multi-tube vortexer (VX-2500,
VWR International, Radnor, PA) and subjected to vortex for
20min at the speed set at 7. Plates were then incubated at 75◦C
for 15min, followed by centrifugation (5min, 2000 × g) to
settle down cell debris. Supernatants were used immediately
in subsequent qRT-PCR reactions or the plates were stored
at−80◦C until use.
Real-time qRT-PCR Assay
The levels of 18S rRNA transcripts from C. parvum and host cells
(referred to as Cp18S andHs18S) were detected by real-time qRT-
PCR method using qScript™ one-step SYBR green qRT-PCR kit
(Quanta Biosciences, Gaithersburg, MD). Cell lysates prepared
as described above were diluted by 100 and 2000 folds for
detecting Cp18S and Hs18S transcripts, respectively. Reactions
were performed in hard-shell 384-well skirted PCR plates (Bio-
Rad Laboratories, Hercules, CA) (10µL/well) containing 3µL
diluted cell lysate, 5µL one-step SYBR green master mix, 0.2µl
RT master mix and the following primers: Cp18S-1011F (5′-TTG
TTC CTT ACT CCT TCA GCA C-3′) and Cp18S-1185R (5′-
TCC TTC CTA TGT CTG GAC CTG-3′) primer pair for Cp18S
rRNA (GenBank accession number: NC_006986.1), and Hs18S-
1F (5′-GGC GCC CCC TCG ATG CTC TTA-3′) and Hs18S-
1R (5′-CCC CCG GCC GTC CCT CTT A-3′) primer pair for
Hs18S rRNA (GenBank accession number: NR_003286). Among
them, Cp18S-1011F and Cp18S-1185R were described in our
earlier studies reporting the original qRT-PCR assay and the
efficacy of S-adenosylhomocysteine hydrolase inhibitors against
the growth of C. parvum in vitro (Cai et al., 2005; Ctrnáctá et al.,
2010), whereas Hs18S-1F and Hs18S-1R represented our newly
optimized primers (that were also described in one of our more
recent publications (Zhang et al., 2012). Hs18S levels were used
as controls and for normalization. All reagents for the qRT-PCR
were loaded using an epMotion 5070 automated pipetting system
(Eppendorf, Hauppauge, NY).
Real-time qRT-PCR reactions were performed by a Bio-Rad
CFX384 Touch Real-Time PCR Detection System. The reactions
started with synthesizing cDNA at 50◦C for 20min, followed by
5min at 95◦C to denature RNA-cDNA hybrids and deactivate
reverse transcriptase, and 40 two-temperature thermal cycles of
PCR amplification at 95◦C, 10 s and 58◦C, 30 s. At the end of PCR
amplification, melting curve analysis was performed between 65
and 95◦C. At least two technical replicates were included in
qRT-PCR reactions for each sample.
After qRT-PCR reactions were completed, amplification
curves and melting peaks were examined to assess the quality
and specificity of the reactions, followed by the computation
of relative parasite loads based on the cycle threshold (CT)
values of Cp18S and Hs18S transcripts as previously described.
Briefly, the means of CT values from technical replicates
were first obtained for individual biological replicates, which
were used to compute △CT values between Cp18S and
Hs18S (i.e., △CT = CT[Cp18S]-CT[Hs18S]), and △△CT values
between each experimental sample and control (i.e., △△CT =
△CT[sample]-△CT[control]). Standard curves were generated by
plotting△CT values against the logarithm of the oocyst numbers
used to inoculate cells, followed by linear regression to obtain
the slope value (parameter A in Equation below) to calculate
the detection efficiency and parasite loads using the following
equation as described (Cai et al., 2005):
Inhibition (%) = (1− 10A·△△CT ) · (100)
Because all samples contained much lower levels of Cp18S rRNA
than those of Hs18S rRNA, we used two different dilution
factors (i.e., 100- and 2000-fold dilutions of lysates for detecting
Cp18S and Hs18S, respectively) as described above to maintain
the linearity of detections. These dilution factors needed to be
considered in calculating the relative level between Cp18S and
Hs18S in a specified sample:
Relative
[
Cp18S
] =
[
Cp18S
]
[Hs18S]
=
(
100
2000
)
· 10A·△CT[Cp18S−Hs18S]
However, the effect of the dilution factors was eliminated in
subsequent computation of the relative growth ofC. parvum (Cp)
between a sample (s) and control (c) based on11C values:
Relative Cp growth =
( [
Cp18S]s
[Hs18S]s )
( [
Cp18S]c
[Hs18S]c )
=
(
100
2000
) · 10A·△CT[s](
100
2000
) · 10A·△CT[c]
= 10A·△△CT[s−c]
Evaluation of the Growth of Host Cells and
Parasite in 96-well Plates
We also evaluated the growth of C. parvum in 96-well plates by
qRT-PCR and microscopy, in which HCT-8 cells were cultured
and infected with C. parvum as described above. For qRT-PCR
analysis, total RNA was isolated from cells using an RNeasy
RNA isolation kit (Qiagen), rather than directly using cell lysates,
to ensure more precise measurements of the levels of Cp18S
and Hs18S transcripts. RNA samples included those from cells
infected with C. parvum for 3 and 44 h, respectively, and from
uninfected cells cultured under the same condition and for the
same time periods. For microscopic examination, sterilized glass
coverslips were gently broken into pieces and placed into selected
wells before seeding host cells. Cells infected with parasites for 3
and 44 h were fixed in 3.7% paraformaldehyde and stained with
a rabbit polyclonal antibody against total C. parvum membrane
proteins following standard protocols (Chen et al., 2003; Zeng
et al., 2006). Samples were then mounted onto glass microscopic
slides with a Anti-Fade mounting medium containing 4′,6-
diamidino-2-phenylindole (DAPI) for counter-staining nuclei
(Molecular Probes, Invitrogen), and examined under Olympus
BX51 Research Microscope.
Assay Quality Assessment
In addition to determining the linear dynamic range from
standard curve derived from samples infected with varied
numbers parasites, the uniformity and signal variability of the
assay were also validated according to the “Assay Guidance
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Manual” (see chapter “HTS Assay Validation” at http://www.
ncbi.nlm.nih.gov/books/NBK53196/) (Iversen et al., 2012). This
method is recommended by the National Center for Advancing
Translational Sciences (NCATS), National Institutes of Health
(NIH) (see “Pre-Clinical Research Toolbox” at http://www.ncats.
nih.gov/expertise/preclinical). In this study, inter-day tests were
performed by three independent experiments. Each experiment
used three 96-well plates to assess inter-plate variations, and
each plate contained three experimental groups, which included
uninfected HCT-8 cells (“Min” background signal), cells infected
with parasites but untreated (“Max” signal), and cells that were
infected with parasites and treated with 120µg/mL (168µM) of
PRM (“Mid” signal). These groups (32 wells each) were arranged
in an interleaved-signal format according to the Assay Guidance
Manual.
The cultivation of host cells and C. parvum in vitro,
preparation of cell lysates, and qRT-PCR assay were performed
as described above. PRM was added into specified wells after the
invasion and the removal of uninfected parasites. At the same
time, DMSO at 0.5% final concentration was added into all wells.
Based on the qRT-PCR data, mean (AVG), standard deviation
(SD), and coefficient of variation (CV) were calculated for each
group in each plate. Signal window (SW) and Z′ factor for each
plate were calculated based on the Assay Guidance Manual as
follows (Iversen et al., 2012):
SW =
(
AVGmax−3SDmax/
√
n
)− (AVGmin+3SDmin/√n)
SDmax/
√
n
Z
′ =
(
AVGmax−3SDmax/
√
n
)− (AVGmin+3SDmin/√n)
AVGmax − AVGmin
Small-scale Drug Screening
The assay is currently used in our laboratory to test drug efficacy
and screen compound libraries against C. parvum in vitro.
Here we report the data on 48 small molecules designated as
C001–C048 to provide a snapshot on the assay performance.
HCT-8 cells were cultured in 96-well plates and infected
with C. parvum using procedures described above. In primary
screening, drugs dissolved in DMSO were added into the culture
immediately after the medium exchange at 3 h post-infection
(hpi) time (10µM final concentration). Each plate contained five
negative controls without receiving drug treatment and three
positive controls treated by 100µg/mL (140µM) of PRM. Each
well, including negative and positive controls, contained 0.5%
DMSO. At 44 hpi time, cell lysates were prepared using Bio-Rad
iScript lysis buffer and the anti-cryptosporidial efficacies of drugs
were evaluated by qRT-PCR as described above. Compounds that
inhibited>65% of the parasite growth were re-tested. Two of the
most effective drugs were then selected to generate dose-response
curves to determine IC50 values.
Results and Discussions
Growth of Host Cells and Parasites in 96-well
Format in the 44-h Infection Assay
Similar to other apicomplexans, Cryptosporidium sporozoites
invade host cells and undergo at least two generation of asexual
cell cycles (merogony) before entering sexual development
(gametogenesis and fertilization between macro- and micro-
gametes) to form oocysts. We have observed that mostC. parvum
cultured in 24- or 48-well plates may complete the second
generation of merogony and a large number of free merozoites
may be released into the culture medium at 48 hpi. This
complicates the quantification of parasite loads because free
merozoites in the medium may be easily washed off during the
sample preparation. To minimize this problem, our laboratory
uses the 44 h infection assay, in which the majority of the
intracellular parasites are in the late stage of meronts and only
a minimal number of merozoites are present in the medium.
To confirm that C. parvum cultured in 96-well plates followed
similar invasion and intracellular developmental timeline, we
compared the parasite growth at 3 and 44 hpi by qRT-PCR and
fluorescence microscopy. We also evaluate the host cell growth at
the time points correlated to the 3 and 44 hpi by qRT-PCR.
Using qRT-PCR, we have observed rapid intracellular parasite
growth (i.e., 34-fold increase of Cp18S rRNA from 3 to 44 hpi)
(Figure 1A), which gave us a good dynamic range to quantify the
relative parasite growth. For comparison, there was only ∼1.6-
fold increase of uninfected Hs18S cultured for the same time
period (Figure 1B), indicating that parasite grew>20 times faster
than the HCT-8 cells in this cultivation system. We also observed
that parasite infection slightly reduced the HCT-8 cell growth
(i.e., ∼10% decrease based on Hs18S rRNA levels) (Figure 1B),
which might be attributed by the arrest of host cell growth
upon infection and cell death upon the completion of merogony
development and the release of parasitemerozoites as reported by
other investigators (Dobbelaere and Küenzi, 2004; Brunet et al.,
2008).
DIC microscopy and IF labeling revealed the successful
invasion of C. parvum sporozoites into the host cells after
3-h initial incubation of oocysts with host cells, in which
the elongated sporozoites were transformed to small round
trophozoites (Figure 1C, 3 hpi panel). However, it was possible
that some sporozoites might have attached to, but failed to
invade into host cells or undergo further development at the
3 hpi time point. The growth of parasite into late stage of
meronts as evidenced by the presence of multiple nuclei in
many meronts by DAPI staining (Figure 1C, 44 hpi panel).
Intracellular parasites in these stages were also clearly visualized
by IF staining using a rabbit antiserum against C. parvum
sporozoite membrane proteins (Figure 1C, TRITC staining).
These observations indicated that parasite cultured in 96-well
plates exhibited an intracellular development timeline similar to
those cultured in 24- and 48-well plates. Because majority of
the parasites still remained intracellular at 44 hpi, they could
be lysed together with host cell monolayers for RNA extraction.
However, we still included a plate centrifugation step before
washing cell monolayers and preparing cell lysates to ensure any
freemerozoites released into themediumwere not excluded from
subsequent analysis.
Optimization the Sample Preparation used for
Simplified qRT-PCR
Several commercial lysis buffers are currently available for
preparing cell lysates suitable for qRT-PCR without further
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FIGURE 1 | Comparison of the growths between Cryptosporidium
parvum and host cells (HCT-8 cell line) cultured in 96-well plates for
44h post-infection (hpi) as determined by detecting their relative levels
of 18S rRNA transcripts. (A) The growth rate of C. parvum in HCT-8 cells
between 3 and 44 hpi. The levels of 18S rRNA transcripts from the parasite
(Cp18S) and host cells (Hs18S) were determined by qRT-PCR, and those of
Hs18S were used for normalization before calculating the fold changes in
Cp18S transcripts. (B) The relative levels of Hs18S in HCT-8 cells infected with
C. parvum for 3 and 44 hpi. Uninfected cells were grown in parallel under the
same condition for the same time periods. Bars represent standard error of the
mean (SEM, n = 9) from three independent experiments. (C) Micrographs
showing the development of C. parvum cultured in HCT-8 cells at 3 and 44 h
post-infection (hpi) time points, in which intracellular parasites were labeled
with a rabbit antiserum against C. parvum sporozoite total membrane proteins
and a TRITC-conjugated goat anti-rabbit IgG secondary antibody and
counter-stained with DAPI for nuclei. DIC, differential inference contrast
microscopy. DAPI, 4′, 6-diamidino-2-phenylindole for counterstaining of nuclei.
TRITC, Tetramethylrhodamine.
purification of RNA (Ho et al., 2013). At the early of the
project, we briefly evaluated Ambion Cells-to-cDNA™ II kit
(Life Technologies) and iScript™ RT-qPCR Sample Preparation
Reagent (Bio-Rad), and observed slight better performance in
releasing intracellular parasite RNA by the Bio-Rad’s reagent
(data not shown) that was then used in our subsequent
assay development. We also observed that standard sample
preparation procedures recommended by the manufacturer was
insufficient to release parasite RNA, largely because intracellular
parasites were contained in parasitophorous vacuoles and
protected by extra layers of membranes. We hence performed
experiments to determine the optimal conditions including the
amounts of lysis buffer and the addition of vortex and heating
steps.
We observed that heat treatment of cell lysates at 75◦C for 10–
30min significantly improved the release of parasite RNA. When
samples were lysed in l00, 150, or 200µL/well lysis buffer, heat
treatment for 10, 20, or 30min reduced the CT[Cp18S] values from
24.4, 24.0, and 23.9 to 22.4, 22.3, and 22.2 in the 100µL/well
group, from 25.3, 24.9, and 24.5 to 23.6, 23.4, and 23.3 in the
150µL/well group, or from 25.6, 25.5, and 25.2 to 23.9, 23.6, and
23.6 in the 200µL/well group, respectively (p < 0.005 by Student
t-test in all samples in comparison to the unheated counterparts)
(Figure 2). However, we also observed certain levels of heat-
induced host cell RNA degradation (i.e., CT[Hs18S] values in
heated samples were increased by ∼0.2–1.0) (Figure 2). One
possible explanation was that the host cell membranes could be
rapidly lysed to release RNA with ice-cold lysis buffer (as heating
was not included in the manufacturer’s protocol), and there was a
small window of time at the beginning of the heating process for
the host cell RNases to become active before being deactivated by
heat. On the other hand, more parasite RNA was released after
the temperature reached to 75◦C and RNases were deactivated.
However, the final host cell RNA concentrations appeared to be
consistent within each experimental group (i.e., CV values at
0.75–3.04% for all groups), indicating that the RNA degradation
would not result in inconsistency in subsequent determination
of relative Hs18S levels. Finally, based on the observation that
heating between 10 and 20min in wells containing 200µL lysis
buffer resulted in the least degradation of host cell RNA (△CT at
0.20–0.25), but the most improvement in releasing parasite RNA
(△CT at−1.8 to−2.0), we determined that the optimal condition
was the use of 200µL iScript™ RT-qPCR Sample Preparation
Reagent and heating for 15min.
The subsequent qRT-PCR amplification protocol in 384-well
format using cell lysates was effective and specific based on
agarose gel analysis of amplicons (data not shown) and post-
run analysis of amplification and melting curves (Figure 3). In
the melting curves, Cp18S and Hs18S displayed two strong and
distinguishable peaks, although there was a small minor peak in
the Cp18S curves (Figure 3B).
Assay Validation on Plate Uniformity, Linear
Dynamic Range, and Drug Testing
Three experimental cell culture groups were used in assay
validation (i.e., a total of 864 uninfected, infected/untreated, and
infected/PRM-treated samples in nine plates). For uninfected
cell samples containing that should not contain any Cp18S
transcripts, the determined Cp18S CT values were resulted from
low level non-specific amplification due to the lack of specific
templates and/or self-amplification of primers, which was similar
to the background signals produced in negative controls without
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FIGURE 2 | Effects of the amount of lysis buffer and heat treatment on the release of RNA from Cryptosporidium parvum and HCT-8 cells. Cell lysates
were first diluted by 100 and 2000 times with nuclease-free water prior to qRT-PCR detection for Cp18S and Hs18S rRNA transcripts, respectively. The plotted CT
values were not calibrated to equal volume of lysis buffer. Bars represent standard error of the mean (SEM, n = 6). Heat treatment vs. un-treatment control, p < 0.005
by Student’s t-test in all samples.
FIGURE 3 | Specific detection of Cp18S and Hs18S rRNA transcripts as demonstrated by amplification curve (A) and melting curve (B) analyses of a
representative plate. Lysates of HCT-8 cells grown in 96-well plates and infected with Cryptosporidium parvum for 44 h were used in qRT-PCR reactions in 384-well
format.
enzyme in a biochemical assay. Under the conditions used
in the assay, the overall mean of CT values for Cp18S from
uninfected cells in all plates was 30.14 (between 29.34 and
31.07). These CT values were much higher than those derived
from cells infected with C. parvum (mean = 22.15, between
21.40 and 22.90) (Table 1). Because of the negative correlation
(inversely proportional) relationship between CT values and
template concentrations, the higher CT values in uninfected cells
indicated that the noise signals in this assay (i.e., background
signals in negative controls in the absence of parasites) were
roughly >250-fold lower than the signals from the infected
cells (i.e., noise levels equivalent to 0.4% of the signals). For
Hs18S transcripts, the overall mean of CT values from all groups
was 13.46 (between 12.92 and 14.06). In the infected/untreated
groups, the average1CT value difference between those of Hs18S
and Cp18S was 8.6 (Table 1). After considering the dilution
factors (i.e., cell lysates used for detecting Hs18S and Cp18S
transcripts were diluted by 100 and 2000 folds, respectively),
these CT values suggested the presence of 7000–8000-fold more
Hs18S than Cp18S in a typical sample.
Using the validation protocols recommended by
NIH/NCATS, we observed high intra-plate, inter-plate, and
inter-day uniformity for the assay (Table 2). All CV values
were <5%, much better than the 20% threshold recommended
by the Assay Guidance Manual. No significant inter-plate and
inter-day data shifts were observed. The SW and Z′ values
in the nine plates were ranging from 17.35 to 44.14 and 0.73
to 0.87, respectively. Both values were much higher than the
recommended acceptance criterions (i.e., SW ≥ 2 and Z′ ≥ 0.4).
The excellence of the assay is largely due to high specificity in the
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TABLE 1 | Summary of the CT values in the uniformity assay using the simplified qRT-PCR assay
a.
Exp Plate Infected, untreated Infected, PRM-treated Uninfected, untreated
Cp18S Hs18S Cp18S Hs18S Cp18S Hs18S
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
1 1 22.24 0.17 13.93 0.17 23.32 4.31 13.55 2.55 30.70 0.25 13.58 0.31
1 2 22.57 0.20 13.77 0.19 23.85 0.30 13.88 0.18 31.07 0.26 12.92 0.30
1 3 22.90 0.53 14.06 0.23 24.47 0.41 13.88 0.25 30.68 0.19 13.69 0.19
2 1 21.67 0.25 13.49 0.25 23.29 0.33 13.51 0.22 30.15 0.29 13.51 0.20
2 2 21.40 0.25 13.32 0.18 23.17 0.27 13.25 0.22 29.68 0.27 13.36 0.29
2 3 21.94 0.52 13.45 0.34 23.65 0.43 13.42 0.34 30.08 0.26 13.42 0.36
3 1 21.93 0.36 13.02 0.38 23.59 0.31 12.99 0.28 29.78 0.26 13.09 0.38
3 2 22.25 0.27 13.33 0.29 23.83 0.31 13.27 0.27 29.34 0.24 13.30 0.25
3 3 22.49 0.41 13.57 0.34 24.09 0.26 13.45 0.30 29.79 0.40 13.44 0.28
aAll mean values are CT values derived from each plate in three independent cell cultivation experiments (Exp) performed in different dates. PRM, paromomycin at 120µg/mL (168µM).
TABLE 2 | Assay validation on the uniformity of the simplified qRT-PCR assay based on normalized △CT values
a.
Exp Plate Infected, untreated Infected, PRM-treated Uninfected, untreated SW Z′ Efficacy of PRM
Mean SD CV (%) Mean SD CV (%) Mean SD CV (%) % Inh SD
1 1 8.31 0.23 2.00 10.08 0.40 2.00 17.12 0.35 1.45 30.40 0.86 69.54 7.84
1 2 8.79 0.20 1.61 9.97 0.32 1.61 18.15 0.36 1.42 31.74 0.87 54.90 10.49
1 3 8.84 0.49 3.94 10.60 0.39 3.94 16.99 0.21 0.89 44.14 0.82 69.34 7.81
2 1 8.18 0.36 3.13 9.78 0.36 3.13 16.64 0.40 1.72 23.94 0.81 66.07 8.30
2 2 8.08 0.36 3.16 9.93 0.33 3.16 16.32 0.38 1.65 24.80 0.81 71.46 6.35
2 3 8.49 0.47 3.95 10.24 0.64 3.95 16.67 0.48 2.02 18.26 0.75 67.30 13.58
3 1 8.91 0.53 4.24 10.59 0.46 4.24 16.68 0.45 1.89 18.06 0.73 67.20 11.32
3 2 8.92 0.31 2.47 10.57 0.44 2.47 16.04 0.33 1.45 24.79 0.81 66.67 10.19
3 3 8.92 0.47 3.77 10.65 0.39 3.77 16.37 0.45 1.94 17.35 0.74 68.82 8.70
aAll mean values are △CT values between Cp18S and Hs18S derived from each plate in three independent cell cultivation experiments (Exp) performed in different dates. % Inh, %
inhibition; PRM, paromomycin at 120µg/mL (168µM); SW, signal window; Z′, Z′ score.
RT-PCR amplification, resulting in a ∼256-fold signal difference
between infected and uninfected samples as described above.
In the PRM-treated groups, the classic anti-cryptosporidial
drug inhibited the parasite growth by 66.07–71.46% in all plates
except for the plate 2 in experiment 1 that was at a slightly lower
level of 54.90% (Table 2). These values were consistent with our
in vitro drug efficacy tests using total RNA samples isolated by
traditional column-based isolation kits from cells cultured in 24-
and 48-well plates (Cai et al., 2005; Zhang et al., 2012; Yu et al.,
2014).
We also generated standard curves from cells infected with
various numbers of parasites. We considered that this approach
was better than the traditional method using serially diluted
RNA templates, because standard curves derived from various
numbers of infected parasites would correct systematic errors
from infection, sample preparation to qRT-PCR procedures,
rather than to only correct the errors introduced at the qRT-
PCR step. In this assay, linear relationship was observed between
the △CT values and the samples isolated from cells infected
with 64–4 × 104 oocysts per well (Figure 4A). The △CT values
from samples infected with more or less parasites frequently
fell outside of the linear range (data not shown). The linear
dynamic range for this new assay (∼156-fold) was smaller than
our previously reported assay using conventional protocols (Cai
et al., 2005). There were two possible explanations. Firstly, the
96-well format had lower limits on the number of parasites that
could be cultured in 96-well without density effect. Secondly, in
comparison to conventional RNA isolation methods, cell lysates
contained much less RNA due to the less efficiency in releasing
RNA by the lysis buffer and higher dilutions needed to minimize
the inhibition of RT-PCR reactions caused by substances present
in the lysis buffer. However, the 156-fold linear dynamic range
was sufficient for testing drug efficacy in vitro, as it could
theoretically resolve <1% changes of parasite loads in the assay
system.
We further evaluated the assay by testing the dose-response of
PRM on the parasite growth, in which the drug at concentrations
from 30 to 800µg/mL reduced the growth of C. parvum by 19–
97%. Using a non-linear curve fit with a sigmoidal model, the
IC50 value was determined at 88.1µg/mL (123µM) (Figure 4B).
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These inhibition values were comparable to those obtained in
our previous report at 89.7µg/ml (Cai et al., 2005), suggesting
that the assay was suitable for determining the inhibitory kinetics
and IC50 values of anti-cryptosporidial compounds identified
by HTS.
Testing the Assay by a Small Scale Drug
Screening
In the primary screening of 48 small molecules (10µM each),
two compounds (C012 and C020) displayed cytotoxicity on
HCT-8 cells, while others displayed a wide range of effects
on the C. parvum growth in vitro (i.e., from −86.6 to 98.8%
inhibition) (Figure 5). The negative inhibition values suggested
that a few compounds might actually promote the parasite
growth and/or affected more on host cells than on parasites,
which could be evaluated by looking at the Hs18S and Cp18S
CT values. For example, for C023 with −86.6% inhibition, the
mean CT values for Hs18S and Cp18S were 13.38 and 18.08
(vs. 13.63 and 19.17 in the DMSO control), suggesting that
this compound likely promoted the parasite growth more than
reducing the host cell growth. Because we were interested only
in identifying anti-cryptosporidial inhibitors in this study, we
repeated the primary testing on the seven most efficacious
compounds, in which six compounds exhibited similar efficacies
(Figure 5A, red circles). We also performed dose-response
experiments on C004 and C028, in which both compounds
at 10µM displayed the same efficacy as observed in the two
primary testing experiments (Figure 5B). Their IC50 values were
at 0.98 and 1.33µM, respectively, suggesting that these two
compounds might be further explored for drug development
or serve as leads. Experiments to further characterize these two
compounds and other top hits from the 48 compounds are
still ongoing as part of our larger effort in discovering new
anti-cryptosporidial drugs, which will be reported separately.
Nonetheless, these observations conformed the robustness and
suitability of the assay in high-throughput screening of drugs by
directly evaluating their anti-cryptosporidial efficacy in vitro.
Conclusions
Wehave developed a simplified real-time qRT-PCR assay suitable
for high-throughput or high-volume screening of drugs against
FIGURE 4 | Evaluation of drug efficacy using the new qRT-PCR assay. (A) Standard curves showing the relationship between the number of inoculated oocysts
and 1CT(Cp18S−Hs18S) values; (B) Dose-response curve on the in vitro anti-cryptosporidial activity of paromomycin. Bars represent standard errors of the mean
(SEM) derived from at least two biological replicates.
FIGURE 5 | In vitro anti-cryptosporidial activities of 48 small molecules (C001–C048). (A) Efficacies of all 48 compounds (10µM each) obtained from primary
screening (solid teal round dots). A second test was performed on seven top hits (red circles), in which six compounds displayed similar levels of efficacy between the
two tests as shown by overlaps or near distances of their corresponding teal dots and red circles. Only one compound showed significantly different efficacies between
the two tests (highlighted by a yellow line to link the corresponding teal dot and red circle). Compound codes are given on the seven top hits and one of the potential
parasite growth enhancer as discussed in the text. (B) Dose-response curves on the anti-cryptosporidial activities of C004 and C028 compounds. Paromomycin at
100µg/ml (140µM) was used as a positive control in this assay. Bars represent standard errors of the mean (SEM) derived from at least two biological replicates.
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the growth of C. parvum in vitro. This was achieved by
directly using cell lysates in qRT-PCR amplification. The assay
was adapted and optimized in 96-well format for culturing
parasite and 384-well format for SYBR-green based one-step
real-time RT-PCR amplification and detection. Intra-plate, inter-
plate, and inter-day uniformities were validated by NIH/NCATS
recommended tests (i.e., SW and Z′ values = 17.35–44.14 and
0.73–0.87, respectively). The assay exhibited >150-fold linear
dynamic range using samples isolated from cells infected with
serially diluted parasites. The robustness and effectiveness of the
assay were also confirmed by evaluating the anti-cryptosporidial
efficacy of paromomycin, and by a small scale screening of 48
compounds.
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